Clinical trials: Patients With Cancer
Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 in combination with cytarabine in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid…
- Trial name
- NCT05241093
- Testing
- HYML-122; cytarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tarapeutics Science Inc.
Breast Cancer, Metastatic Invasive Lobular Breast Cancer
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
This study is a pilot clinical imaging trial of a prospective, head-to-head comparison of 18F-Fibroblast Activation Protein Inhibitor (FAPI)-74 PET/CT versus standard-of-care 18F-Fluorodeoxyglucose (FDG) PET/CT in 15 patients…
- Trial name
- NCT07285993
- Testing
- 18F-FAPI-74, 18F-FDG, PET/CT
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Randy Yeh
Ovarian Cancer
A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
This multicenter, open-label, dose-escalating study will assess the safety, tolerability, and pharmacokinetics of DMOT4039A in participants with unresectable pancreatic or platinum-resistant ovarian cancer.
- Trial name
- NCT01469793
- Testing
- DMOT4039A
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 71 people
- Sponsor
- Genentech, Inc.
Non Small Cell Lung Cancer
A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin…
- Trial name
- NCT00606021
- Testing
- pemetrexed, Best Supportive Care
- Where
- 5 sites in Egypt, Lebanon and 1 more
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
- Trial name
- HARMONi-7 (NCT06767514)
- Testing
- Ivonescimab Injection, Pembrolizumab Injection
- Where
- 285 sites in United States, Belgium and 15 more
- Volunteers
- 780 people
- Sponsor
- Summit Therapeutics
Brain Tumors
Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Bradmer Pharmaceuticals, Inc. (Bradmer) is requesting approval to study the safety of Neuradiab® when combined with Bevacizumab (Avastin) therapy given at a minimum of 30 days after Neuradiab administration in patients with a…
- Trial name
- NCT00906516
- Testing
- Neuradiab in combination with Bevacizumab (Avastin)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Bradmer Pharmaceuticals Inc.
Metastatic Solid Tumors.
Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.
This is a phase II, multi-center (Israeli), open label, non-randomized trial for every patient with the specified tumors expressing c-kit or PDGFR.
- Trial name
- NCT00159016
- Testing
- Glivec
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Hadassah Medical Organization
Unspecified Adult Solid Tumor, Protocol Specific
LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy drugs may have different effects in patients with different degrees of kidney function.
- Trial name
- NCT00003706
- Testing
- pemetrexed disodium
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Unresectable Metastatic Colorectal Cancer
OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer
Evaluation of feasibility of adding aflibercept to an oxaliplatin-based regimen rather than a continuous administration of chemotherapy until progression, in order to decrease the risk of severe toxicities.
- Trial name
- VELVET (NCT01802684)
- Testing
- aflibercept
- Where
- 8 sites in France
- Volunteers
- 49 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Efficacy and Safety Study of Neoadjuvant in Treating Patients With Resectable Local Recurrent Rectal Cancer
RATIONALE: Surgical resection and adjuvant therapy has become the main treatment for resectable local recurrent rectal cancer. However the efficacy and safety of adjuvant therapy is still unknown.
- Trial name
- NARC (NCT01271192)
- Testing
- surgical resection and adjuvant therapy, Neoadjuvant followed by operation
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Sun Yat-sen University
Multiple Myeloma
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT03269136
- Testing
- PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide
- Where
- 37 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Pfizer
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after…
- Trial name
- NCT06232044
- Testing
- Iberdomide, Belantamab Mafodotin, Dexamethasone
- Where
- 43 sites in United States
- Volunteers
- 88 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukemia
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of R115777 in treating patients who have refractory or…
- Trial name
- NCT00004009
- Testing
- tipifarnib
- Where
- 3 sites in United States
- Sponsor
- University of Maryland, Baltimore
Lung Cancer, Quality of Life
Improving Supportive Care For Patients With Thoracic Malignancies
The purpose of this study is to use a proactive approach to improve symptom management of patients with thoracic malignancies and ensure receipt of evidence-based cancer care delivery.
- Conditions
- Lung Cancer, Quality of Life, Supportive Care
- Trial name
- NCT03216109
- Testing
- Weekly telephone symptom assessment
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Palo Alto Veterans Institute for Research
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or…
- Trial name
- NCT04172532
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 44 sites in United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Cancer
Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
Differentiated thyroid cancer includes papillary, follicular, Hurthle cell, and C-cell/medullary carcinoma. Even though incidence is relatively low (1% of all neoplasms), a rise in this disease has been recorded in the country…
- Trial name
- NCT02084732
- Testing
- Sorafenib
- Where
- Colombia
- Volunteers
- 35 people
- Sponsor
- Instituto Nacional de Cancerologia, Columbia
Endometrial Cancer
Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00085332
- Testing
- docetaxel
- Where
- 75 sites in United States, Australia and 3 more
- Sponsor
- Gynecologic Oncology Group
Colorectal Cancer
Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
This study is for people with colorectal cancer, who have tumors that cannot be completely removed by surgery. This study is being done to find out how long it takes tumors to grow after patients receive the drugs capecitabine…
- Trial name
- NCT00159432
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Southern California
Prostate Cancer
Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients
This is a pilot study of implement multi-parametric MR imaging for organ delineation and tumor response assessment of prostate cancer patients being treated with radiation therapy.
- Trial name
- NCT03180398
- Testing
- Multiparametric MRI
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.